UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential
In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00.
In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”
AbbVie closed on Thursday at $43.04.
Latest Ratings for ABBV
|Jan 2015||Bank of America||Downgrades||Buy||Neutral|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.